Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
Maloisel F, Guerci A, Guyotat D, Ifrah N, Michallet M, Reiffers J, Tertain G, Blanc M, Bauduer F, Brière J, Abgrall JF, Pegourie-Bandelier B, Solary E, Cambier N, Coso D, Vilque JP, Delain M, Harousseau JL, Rousselot P, Belhadj K, Morice P, Attal J, Chabin M, Chastang C, Guilhot J, Guilhot F; France Intergroupe des Leucémies Myéloïdes Chroniques. Maloisel F, et al. Among authors: harousseau jl. Leukemia. 2002 Apr;16(4):573-80. doi: 10.1038/sj.leu.2402433. Leukemia. 2002. PMID: 11960335 Clinical Trial.
A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
Guilhot F, Abgrall JF, Harousseau JL, Bauters F, Brice P, Dine G, Tilly H, Ifrah N, Cassasus P, Rochant H, et al. Guilhot F, et al. Among authors: harousseau jl. Leuk Lymphoma. 1993;11 Suppl 1:181-3. doi: 10.3109/10428199309047883. Leuk Lymphoma. 1993. PMID: 8251893 Clinical Trial.
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, Michallet M, Doyen C, Leyvraz S, Mohty M, Wetterwald M, Mathiot C, Caillot D, Berthou C, Benboubker L, Garderet L, Chaleteix C, Traullé C, Fuzibet JG, Jaubert J, Lamy T, Casassus P, Dib M, Kolb B, Dorvaux V, Grosbois B, Yakoub-Agha I, Harousseau JL, Avet-Loiseau H; SAKK; IFM Group. Moreau P, et al. Among authors: harousseau jl. Leukemia. 2007 Sep;21(9):2020-4. doi: 10.1038/sj.leu.2404832. Epub 2007 Jul 12. Leukemia. 2007. PMID: 17625611
The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.
Guilhot F, Guerci A, Fiere D, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Rochant H, Najman A, Nicolini F, Colombat P, Abgrall JF, Ifrah N, Brière J, Bauters F, Navarro M, Morice P, Bordessoule D, Vilque JP, Desablens B, Tertian G, Blanc M, Chastang C, Tanzer J. Guilhot F, et al. Among authors: harousseau jl. Bone Marrow Transplant. 1996 May;17 Suppl 3:S29-31. Bone Marrow Transplant. 1996. PMID: 8769697 Clinical Trial. No abstract available.
552 results